Ad is loading...
CABA
Price
$1.89
Change
+$0.02 (+1.07%)
Updated
Nov 22, 03:17 PM (EDT)
111 days until earnings call
ENTO
Price
$0.43
Change
+$0.02 (+4.88%)
Updated
Nov 22, 02:48 PM (EDT)
Ad is loading...

CABA vs ENTO

Header iconCABA vs ENTO Comparison
Open Charts CABA vs ENTOBanner chart's image
Cabaletta Bio
Price$1.89
Change+$0.02 (+1.07%)
Volume$3.5K
CapitalizationN/A
Entero Therapeutics
Price$0.43
Change+$0.02 (+4.88%)
Volume$1K
CapitalizationN/A
CABA vs ENTO Comparison Chart
Loading...
CABA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ENTO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
CABA vs. ENTO commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CABA is a Hold and ENTO is a Hold.

COMPARISON
Comparison
Nov 23, 2024
Stock price -- (CABA: $1.87 vs. ENTO: $0.41)
Brand notoriety: CABA and ENTO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CABA: 536% vs. ENTO: 5%
Market capitalization -- CABA: $91.4M vs. ENTO: $1.97M
CABA [@Biotechnology] is valued at $91.4M. ENTO’s [@Biotechnology] market capitalization is $1.97M. The market cap for tickers in the [@Biotechnology] industry ranges from $463.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CABA’s FA Score shows that 1 FA rating(s) are green whileENTO’s FA Score has 1 green FA rating(s).

  • CABA’s FA Score: 1 green, 4 red.
  • ENTO’s FA Score: 1 green, 4 red.
According to our system of comparison, ENTO is a better buy in the long-term than CABA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CABA’s TA Score shows that 4 TA indicator(s) are bullish while ENTO’s TA Score has 4 bullish TA indicator(s).

  • CABA’s TA Score: 4 bullish, 5 bearish.
  • ENTO’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both CABA and ENTO are a bad buy in the short-term.

Price Growth

CABA (@Biotechnology) experienced а -50.53% price change this week, while ENTO (@Biotechnology) price change was -20.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.14%. For the same industry, the average monthly price growth was -4.97%, and the average quarterly price growth was +4.04%.

Reported Earning Dates

CABA is expected to report earnings on Mar 13, 2025.

Industries' Descriptions

@Biotechnology (+2.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CABA($91.4M) has a higher market cap than ENTO($1.97M). ENTO (-90.119) and CABA (-91.762) have similar YTD gains . ENTO has higher annual earnings (EBITDA): -18.46M vs. CABA (-112.92M). CABA has more cash in the bank: 183M vs. ENTO (367K). ENTO has less debt than CABA: ENTO (160K) vs CABA (15.2M). CABA (0) and ENTO (0) have equivalent revenues.
CABAENTOCABA / ENTO
Capitalization91.4M1.97M4,633%
EBITDA-112.92M-18.46M612%
Gain YTD-91.762-90.119102%
P/E RatioN/A0.03-
Revenue00-
Total Cash183M367K49,864%
Total Debt15.2M160K9,500%
FUNDAMENTALS RATINGS
ENTO: Fundamental Ratings
ENTO
OUTLOOK RATING
1..100
80
VALUATION
overvalued / fair valued / undervalued
1..100
7
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
66
P/E GROWTH RATING
1..100
92
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CABAENTO
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 17 days ago
87%
Bullish Trend 22 days ago
82%
Declines
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
CABA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ENTO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NBSMX54.100.96
+1.81%
Neuberger Berman Small Cap Growth Instl
HQITX22.950.24
+1.06%
Hartford Equity Income R5
FGETX25.090.16
+0.64%
Fidelity Advisor Glbl Capital Apprec M
GCHDX13.50N/A
N/A
Gotham Hedged Core Institutional
GGGPX43.79N/A
N/A
Goldman Sachs Large Cap Core P

CABA and

Correlation & Price change

A.I.dvisor indicates that over the last year, CABA has been loosely correlated with PLRX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if CABA jumps, then PLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CABA
1D Price
Change %
CABA100%
-17.26%
PLRX - CABA
40%
Loosely correlated
+0.94%
RCKT - CABA
40%
Loosely correlated
-1.92%
IDYA - CABA
38%
Loosely correlated
+4.15%
ALLO - CABA
38%
Loosely correlated
+2.93%
SLRN - CABA
37%
Loosely correlated
-2.26%
More

ENTO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTO has been loosely correlated with IVVD. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTO jumps, then IVVD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTO
1D Price
Change %
ENTO100%
+3.49%
IVVD - ENTO
60%
Loosely correlated
-8.89%
RLMD - ENTO
36%
Loosely correlated
-3.51%
CABA - ENTO
35%
Loosely correlated
-17.26%
IMMP - ENTO
29%
Poorly correlated
-6.12%
MEOBF - ENTO
24%
Poorly correlated
+8.25%
More